1010
Ana Teresa Timóteo
18. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its
complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a
WHO consultation. Diabet Med 1998; 15: 539-553.
19. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment oh High Blood Cholesterol in Adults (Adult Treatment
Panel III) final report. Circulation 2002; 106: 3143-3421.
20. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on
Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart
Association; World Heart Federation; International Atherosclerosis Society; International
Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint inte-
rim statement of the International Diabetes Federation Task Force on Epidemiology and
Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World
Heart Federation; International Atherosclerosis Society; and International Association for
the Study of Obesity. Circulation. 2009; 120: 1640-5.
21. Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Accuracy of body mass index in diag-
nosis obesity in the adult general population. Int J Obes. 2008; 32: 959-966.
22. Beechy L, Galpern J, Petrone A, et al. Assessment tools in obesity – psychological measures,
diet, activity and body composition.
Physiol Behav. 2012; 107: 154-171
23. Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity
in adults. National Heart, Lung, and Blood Institute. National Institute of Health Publication
No98 – 4083. September 1998 (Acesso on-line a 10/07/2015).
24. Van Gaal LC, Scheen AJ, Rissanen AM, et al. Long-term effect of CB1 blockade with rimona-
bant on cardiovascular risk factors: two year results from the RIO-Europe study. Eur Heart
J. 2008; 29: 1761-1771.
25. Van Gaal LF, Caterson ID, Coutinho W, et al. Weight and blood pressure response to weight
management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from
the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Dia-
betes Obes Metab. 2010; 12: 26-34.
26. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outco-
mes in overweight and obese subjects. N Engl J Med. 2010; 363: 905-917.
27. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight:
updated meta-analysis BMJ. 2007; 335: 1194-1199.
28. Phillips SA, Kung JT. Mechanisms of adiponectin regulation and use as a pharmacological
target. Curr Opin Pharmacol. 2010; 10: 1-8.
29. Stone NJ, Robinson JG, Lichenstein AH et al. 2013 ACC/AHA guidelines on the treatment of
blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;
129: S1-S45.
30. Reiner Z, Catapano AL, DeBacker G, et al. ESC / EAS Guidelines for the management of
dyslipidemias. Eur Heart J. 2011; 32: 1769-1818.
31. Ryden L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovas-
cular diseases developed in collaboration with the EASD. Eur Heart J. 2013; 34: 3035-3087.
